BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9473251)

  • 1. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins.
    Spyridonidis A; Schmidt M; Bernhardt W; Papadimitriou A; Azemar M; Wels W; Groner B; Henschler R
    Blood; 1998 Mar; 91(5):1820-7. PubMed ID: 9473251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34(+) blood progenitor cells.
    Spyridonidis A; Bernhardt W; Behringer D; Köhler G; Azemar M; Pflug A; Henschler R
    Blood; 1999 Jan; 93(2):746-55. PubMed ID: 9885238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
    Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
    Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
    Vogel W; Behringer D; Scheding S; Kanz L; Brugger W
    Blood; 1996 Oct; 88(7):2707-13. PubMed ID: 8839866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
    Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
    Schmidt M; Vakalopoulou E; Schneider DW; Wels W
    Br J Cancer; 1997; 75(11):1575-84. PubMed ID: 9184171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective elimination of breast cancer cells from human bone marrow using an antibody-Pseudomonas exotoxin A conjugate.
    Bjorn MJ; Manger R; Sivam G; Morgan AC; Torok-Storb B
    Cancer Res; 1990 Sep; 50(18):5992-6. PubMed ID: 2118424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
    LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
    Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
    Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
    Oncogene; 1999 Mar; 18(9):1711-21. PubMed ID: 10208432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
    Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
    Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
    Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
    Wels W; Harwerth IM; Mueller M; Groner B; Hynes NE
    Cancer Res; 1992 Nov; 52(22):6310-7. PubMed ID: 1358432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-free ex vivo expansion of CD34(+) hematopoietic progenitor cells.
    Möbest D; Mertelsmann R; Henschler R
    Biotechnol Bioeng; 1998 Nov; 60(3):341-7. PubMed ID: 10099437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein.
    Fischer PH; Bird RE; Kasprzyk PG; King CR; Turner NA; Pastan I; Kihara A; Batra J
    Adv Enzyme Regul; 1994; 34():119-28. PubMed ID: 7942269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
    Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
    ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cell surface antigens as potential targets for recombinant tumor toxins.
    Wick B; Groner B
    Cancer Lett; 1997 Oct; 118(2):161-72. PubMed ID: 9459206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
    Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
    Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.